Ahmed Massoud has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Neuroprotective effects of Moringa oleifera leaf extract via potential NF-κB modulation in cuprizone-induced demyelination in rats: Integrated in vivo and in silico evidence

    by Amina E. Essawy, Rania I. Fahmy, Rehab A. Gomaa, Howida A. Fetouh, Mohamed Helal, Ahmed Massoud, Mohamed A. Hassan, Wessam M. Abdel-Wahab

  • Repurposing approved drugs as ferroptosis modulators: a critical review of clinical trials in cancer and neurodegeneration

    by Mohammed Zayed, Ahmed Massoud, Enas Elwakeel, Prehan Ezzat, Yaser Alammar, Nessma A. Abd El-Wahab, Rahma W. Afifi, Byung-Hoon Jeong

    Ferroptosis is a regulated form of cell death that depends on iron and is marked by lipid peroxidation and the inactivation of glutathione peroxidase 4. It has emerged as a pathway of broad relevance to cancer and neurodegenerative disease. Preclinical studies have identified potent ferroptosis inducers (System Xc⁻ and GPX4 inhibitors) and inhibitors (liproxstatin/ferrostatin derivatives, FSP1–CoQ10 activators) with promising therapeutic potential. However, clinical translation remains limited. Since dedicated therapeutics targeting ferroptosis are still in early development, current clinical evidence mainly comes from drug repurposing, approved drugs whose ferroptosis-modulating properties were discovered retrospectively after their initial approval. None of these completed trials used ferroptosis-specific pharmacodynamic data or prospectively tested ferroptosis as the primary therapeutic mechanism. Instead of just reclassifying these trials, this review introduces a four-category failure-mode framework, mechanism mismatch, biomarker absence, model-to-trial prediction, and target non-selective compound, to explain why preclinical signals of ferroptosis have yet to translate successfully. We conclude that progress depends on three developments: targeted modulators (purpose-developed or repurposed with confirmed engagement), proof-of-mechanism trials using ferroptosis-related endpoints, and patient selection aligned with precision medicine.


  • Open Access

    Betanin from Beta vulgaris Attenuates Complete Freund’s Adjuvant-Induced Inflammatory Pain: Integrated Preclinical and In Silico Insights

    by Ahmed Massoud, Amina E. Essawy, Mohammed A. Alfredan, Ashraf M. Abdel-Moneim, Rehab A. Gomaa, Sherine Abdel Salam

    Background/Objectives: Betanin (BET), a prominent phytochemical mainly derived from Beta vulgaris, exhibits strong anti-inflammatory and antioxidant activities owing to its distinctive chemical structure. Nevertheless, its potential analgesic effect in the context of inflammatory pain remains insufficiently explored. Accordingly, this study investigated the analgesic effects of BET in a complete Freund’s adjuvant (CFA)-induced rat model of inflammatory pain. Methods: Rats received a single subcutaneous injection of 100 µL CFA to induce inflammatory pain, followed by oral administration of BET at doses of 40 or 80 mg/kg/day for 14 days. Results: BET treatment significantly reduced paw edema and improved HPL (hot plate latency) in CFA-injected rats. Biochemically, in the ipsilateral spinal cord of rats, BET at both 40 and 80 mg/kg significantly increased IL-4, and only the 80 mg/kg dose significantly reduced oxidative stress (MDA) and IL-1β. TNF-α levels were slightly reduced at both doses and did not reach statistical significance versus CFA. At the molecular level, miR-107 was significantly downregulated by BET at 80 mg/kg (but not 40 mg/kg), while miR-145 was significantly upregulated by both 40 mg/kg and 80 mg/kg compared to CFA. Pearson’s correlation indicated that miR-107 was positively correlated with MDA, IL-1β and TNF-α but negatively with IL-4, whereas miR-145 was positively correlated with IL-4 but negatively with IL-1β. PCA biplot analysis corroborated these findings, showing simultaneous presence of MDA, IL-1β, TNF-α, and miR-107 with CFA, and IL-4 and miR-145 were only related to control and CFA+BET80 groups. In addition, using transmission electron microscopy imaging, we found that BET alleviated neuronal damage in CFA-treated rats. Furthermore, molecular docking analysis predicted that BET may exhibit stable binding interactions with several inflammation- and apoptosis-related targets, including AKT1, mTOR, IKKβ, TNF-α, IL-1β, COX-2, caspase-3, caspase-7, and caspase-8, supporting its multi-target anti-inflammatory and antiapoptotic effects. Conclusions: Overall, our data suggest that BET can possibly exert analgesic effects in CFA-induced inflammatory pain by modulating oxidative stress and favoring a shift toward an anti-inflammatory status. These effects coincided with downregulation of miR-107, overexpression of miR-145, and improvements in inflammatory pain behaviors. Further investigations are required to validate the involvement of specific miRNA- and pathway-mediated effects. Nevertheless, our findings highlight BET as a promising natural candidate for future development of anti-inflammatory and analgesic strategies.


  • Integrating Single-Cell Sequencing and Proteomics to Unravel Stem Cell Heterogeneity: Implications for Precision Regenerative Medicine

    by Mohammed Zayed, Ahmed Massoud, Roya Al-Haddad, Ahmed Al-Kubaisi, Walid Said, Amany Atiaa, Byung-Hoon Jeong


  • The SLC7A11 Thermostat: A Molecular Signaling Switch Between Ferroptosis and Disulfidptosis in Neurodegenerative Disease

    by Mohammed Zayed, Maha Mahmoud, Ahmed Massoud, Renad Darwish, Byung-Hoon Jeong

    Neurodegenerative diseases are characterized by a metabolic paradox, a balance regulated at the molecular level by a narrow set of redox-sensitive signaling checkpoints. The cystine/glutamate antiporter SLC7A11 plays a central role in this challenge. Traditionally recognized as an antioxidant guardian that prevents ferroptosis through NRF2-KEAP1-driven glutathione synthesis, SLC7A11 can become a burden under metabolic stress. Under glucose restriction or mitochondrial dysfunction, impaired NADPH regeneration prevents cells from reducing imported cystine, leading to disulfide stress in cytoskeletal actin-binding proteins and a novel form of regulated cell death called disulfidptosis. We suggest that neural cell fate and intercellular redox support depend not only on the presence of SLC7A11 activity but also on its specific calibration in each cell type, taking into account cystine availability, glutamate management, and NADPH regeneration. Since baseline system Xc⁻ activity in the CNS is primarily observed in astrocytes and microglia, this regulatory mechanism may operate both within individual cells and across cell types via the astrocyte–neuron metabolic network. Within this proposed framework, insufficient SLC7A11 activity may increase ferroptotic susceptibility, whereas sustained cystine uptake under severe NADPH limitation may create conditions permissive for disulfidptosis. In Alzheimer’s disease, chronic cerebral glucose hypometabolism might lead to disulfide stress in neural cells with high SLC7A11 levels, although the typical disulfidptosis process has not yet been confirmed in vivo. We argue that traditional antioxidant supplements or SLC7A11 modulation are unlikely to succeed without understanding this dual-risk profile at the level of molecular pathways. We propose shifting toward precise adjustment via biomarker-guided redox modulators and metabolic priming to enhance NADPH reserves. By examining SLC7A11 as a dynamic molecular regulator, this review offers a hypothesis-generating framework that may help resolve conflicting findings and inform the development of focused neuroprotective approaches relevant to the molecular neurobiology of neurodegenerative disease.


  • Harnessing Adipose Ferroptosis: A Promising Novel Pathway for Obesity Treatment

    by Mohammed Zayed, Ahmed Massoud, Fatma Hassan, Enas Elwakeel, Yusuf Mahmoud, Byung-Hoon Jeong

    Purpose of Review This review summarizes the potential of targeting ferroptosis-iron-dependent lipid peroxidation-as a novel strategy for treating obesity and its metabolic complications through mechanisms different from traditional interventions. Recent Findings Recent preclinical studies show that selectively inducing ferroptosis in lipid-rich adipocytes and obese mice can effectively decrease fat mass and enhance metabolic health. These ferroptosis-based methods target the fundamental cellular processes of adipocyte dysfunction, affecting lipid metabolism and reducing oxidative stress. The strategy appears promising in addressing major metabolic issues such as insulin resistance and hepatic steatosis. In addition, the ability to customize ferroptosis inducers based on individual metabolic profiles offers a pathway to highly personalized obesity treatments. Summary Ferroptosis agonists offer a revolutionary therapeutic approach for obesity treatment by directly reducing fat mass and targeting key metabolic issues. However, applying these findings in clinical settings requires careful evaluation of the long-term safety and effects of pharmacological ferroptosis induction. This review highlights important gaps in current knowledge and suggests future research directions crucial for developing these innovative therapies.